Treating Dysfunction of Resistance Arteries to Restore Blood Flow with Dr. Steffen-Sebastian Bolz QanatPharma TRANSCRIPT
Release Date: 09/14/2026
Role of Cloud Fax in Fast and Secure Healthcare Messaging with Marcus Ionker Retarus TRANSCRIPT
Empowered Patient Podcast
Marcus Ionker, Product Line Manager and Messaging Evangelist at Retarus, which is a cloud-based transactional electronic messaging service provider offering fax, SMS, email, and logistics services to regulated industries like healthcare. By moving fax to the cloud, Retarus helps providers and payers reduce administrative costs, improve patient services, and comply with privacy regulations. The company is addressing the critical challenge of providing reliable, secure, and fast messaging to replace outdated physical fax machines and to eliminate paper-based processes in favor of digital...
info_outline
Role of Cloud Fax in Fast and Secure Healthcare Messaging with Marcus Ionker Retarus
Empowered Patient Podcast
Marcus Ionker, Product Line Manager and Messaging Evangelist at Retarus, which is a cloud-based transactional electronic messaging service provider offering fax, SMS, email, and logistics services to regulated industries like healthcare. By moving fax to the cloud, Retarus helps providers and payers reduce administrative costs, improve patient services, and comply with privacy regulations. The company is addressing the critical challenge of providing reliable, secure, and fast messaging to replace outdated physical fax machines and to eliminate paper-based processes in favor of digital...
info_outline
Disease-Modifying Allogeneic Treatment for Chronic Sciatica with Andrew Hall Consano Bio TRANSCRIPT
Empowered Patient Podcast
Andrew Hall, CEO of Consano Bio, is developing an allogeneic approach to treat chronic sciatica by activating healing in damaged spinal nerves, emulating the natural healing properties of human platelets. This condition currently has no approved treatments and is managed through symptomatic approaches like opioids, muscle relaxers, or surgery. Consano Bio's lead candidate represents the first potential disease-modifying therapy for pain management and can be manufactured at scale to treat the estimated 10 million Americans affected by this condition. Andrew explains, "We are developing...
info_outline
Disease-Modifying Allogeneic Treatment for Chronic Sciatica with Andrew Hall Consano Bio
Empowered Patient Podcast
Andrew Hall, CEO of Consano Bio, is developing an allogeneic approach to treat chronic sciatica by activating healing in damaged spinal nerves, emulating the natural healing properties of human platelets. This condition currently has no approved treatments and is managed through symptomatic approaches like opioids, muscle relaxers, or surgery. Consano Bio's lead candidate represents the first potential disease-modifying therapy for pain management and can be manufactured at scale to treat the estimated 10 million Americans affected by this condition. Andrew explains, "We are developing...
info_outline
How Real-Time Location Data and AI Improve Utilization of Clinic Exam Rooms with Isobel Handler Kontakt io TRANSCRIPT
Empowered Patient Podcast
Isobel Handler, Senior Director of Product Management at Kontakt.io addresses critical inefficiencies in clinical exam room utilization. By capturing data about staff-patient interactions and facility usage, the Kontakt.io platform incorporates real-time location data to optimize patient access, reduce waiting time, and improve staff safety. The solution helps healthcare organizations understand their current capacity utilization before investing in new facilities and supports integration of digital tools to include virtual visits and asychronous communication to better serve patients...
info_outline
How Real-Time Location Data and AI Improve Utilization of Clinic Exam Rooms with Isobel Handler Kontakt io
Empowered Patient Podcast
Isobel Handler, Senior Director of Product Management at Kontakt.io addresses critical inefficiencies in clinical exam room utilization. By capturing data about staff-patient interactions and facility usage, the Kontakt.io platform incorporates real-time location data to optimize patient access, reduce waiting time, and improve staff safety. The solution helps healthcare organizations understand their current capacity utilization before investing in new facilities and supports integration of digital tools to include virtual visits and asychronous communication to better serve patients...
info_outline
Treating Dysfunction of Resistance Arteries to Restore Blood Flow with Dr. Steffen-Sebastian Bolz QanatPharma TRANSCRIPT
Empowered Patient Podcast
Dr. Steffen-Sebastian Bolz, Founder of QanatPharma, emphasizes the critical role of resistance arteries, microscopic blood vessels that regulate blood flow and pressure throughout the body, in maintaining organ function. Due to their size, these resistance arteries have been overlooked but with new lab techniques, QP is discovering how their dysfunction contributes to heart failure, cognitive impairment and strokes. The company's lead candidate is a repurposed drug already approved for cystic fibrosis that shows promise in restoring brain blood flow and cognitive function in heart failure...
info_outline
Treating Dysfunction of Resistance Arteries to Restore Blood Flow with Dr. Steffen-Sebastian Bolz QanatPharma
Empowered Patient Podcast
Dr. Steffen-Sebastian Bolz, Founder of QanatPharma, emphasizes the critical role of resistance arteries, microscopic blood vessels that regulate blood flow and pressure throughout the body, in maintaining organ function. Due to their size, these resistance arteries have been overlooked but with new lab techniques, QP is discovering how their dysfunction contributes to heart failure, cognitive impairment and strokes. The company's lead candidate is a repurposed drug already approved for cystic fibrosis that shows promise in restoring brain blood flow and cognitive function in heart failure...
info_outline
Drug Inhibits Epigenetic Enzyme To Treat Leukemia and Neuropsychiatric Disorders with Carlos Buesa Oryzon Genomics TRANSCRIPT
Empowered Patient Podcast
Carlos Buesa, CEO of Oryzon Genomics, specializes in developing precision medicine based on epigenetics, the regulatory mechanisms that control gene expression without altering the DNA. A key target is the LSD1 enzyme which regulates cell differentiation and is a factor in acute myeloid leukemia and CNS disorders. LSD1 inhibition addresses a fundamental insight that the same dysregulated epigenetic genes implicated in leukemia also drive various neruopsychiatric and genetic syndromes suggesting a unified mechanistic understanding of diverse diseases. Carlos explains, "Epigenetics has...
info_outline
Drug Inhibits Epigenetic Enzyme To Treat Leukemia and Neuropsychiatric Disorders with Carlos Buesa Oryzon Genomics
Empowered Patient Podcast
Carlos Buesa, CEO of Oryzon Genomics, specializes in developing precision medicine based on epigenetics, the regulatory mechanisms that control gene expression without altering the DNA. A key target is the LSD1 enzyme which regulates cell differentiation and is a factor in acute myeloid leukemia and CNS disorders. LSD1 inhibition addresses a fundamental insight that the same dysregulated epigenetic genes implicated in leukemia also drive various neruopsychiatric and genetic syndromes suggesting a unified mechanistic understanding of diverse diseases. Carlos explains, "Epigenetics has...
info_outlineDr. Steffen-Sebastian Bolz, Founder of QanatPharma, emphasizes the critical role of resistance arteries, microscopic blood vessels that regulate blood flow and pressure throughout the body, in maintaining organ function. Due to their size, these resistance arteries have been overlooked but with new lab techniques, QP is discovering how their dysfunction contributes to heart failure, cognitive impairment and strokes. The company's lead candidate is a repurposed drug already approved for cystic fibrosis that shows promise in restoring brain blood flow and cognitive function in heart failure patients.
Steffen-Sebastian explains, "So what we would consider resistance arteries is anything between the capillary level, which would be 10 micrometers, up to, let's say, a few hundred micrometers. And 300 micrometers is the thickness of a blonde hair. That's kind of what we're talking about here. And everything else, and what I talk about in function is what I said before: they can change their diameter. They can open up or close, which large arteries can not do. They are stiff as a garden hose. They are conduits with arteries. They are made to conduct blood at the lowest resistance possible, whereas the small resistance arteries are made to change resistance and regulate flow and pressure."
"As I said, these small resistance arteries and capillaries are everywhere. Every organ has them. And if you compromise the function of those resistance arteries, you compromise blood flow to the capillaries, which actually means that the capillaries don't get enough oxygen. They cannot transport CO2 away from the tissues. They don't get enough nutrients and so on, which then leads to functional damage, which is number one."
"And if it persists, if the problem persists, it can also lead to structural damage, which we can actually see. You mentioned the heart. The heart can deal with it, and also the brain can deal with reductions in that flow to a certain extent. But if the reduction in blood flow exceeds a certain limit, you get structural damage. And we see that structural damage. And we call them infarctions in the heart, but also in the brain, which is a stroke."
#QanatPharma #VascularBiology #MicrovascularHealth #DrugDiscovery #HeartFailure #CognitiveImpairment #BiotechInnovation #PrecisionMedicine #AIinDrugDiscovery#Microvascular #Neurology #DrugRepurposing #Cardiology #MedicalResearch #ClinicalTrials #Hypertension
